BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29281201)

  • 1. [Changed percentage of myeloid-derived suppressor cells in the peripheral blood of prostate cancer patients and its clinical implication].
    Zhou QZ; Liu CD; Yang JK; Guo WB; Zhou JH; Bian J
    Zhonghua Nan Ke Xue; 2016 Nov; 22(11):963-967. PubMed ID: 29281201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
    Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
    Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma.
    Pu LF; Li MM; Feng XJ; Zhang T; Hu LH; Zheng HM; Charwudzi A; Ding YY; Liu J; Liu ZL; Xiong SD
    J Leukoc Biol; 2024 May; 115(6):1094-1107. PubMed ID: 38369808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral expansion of myeloid-derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies.
    Torres-Ruiz J; Absalón-Aguilar A; Reyes-Islas JA; Cassiano-Quezada F; Mejía-Domínguez NR; Pérez-Fragoso A; Maravillas-Montero JL; Núñez-Álvarez C; Juárez-Vega G; Culebro-Bermejo A; Gómez-Martín D
    Rheumatology (Oxford); 2023 Feb; 62(2):775-784. PubMed ID: 35766810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distribution of myeloid-derived suppressor cells subsets and up-regulation of programmed death-1/PD-L1 axis in peripheral blood of adult CAP patients.
    Gong H; Zhao J; Xu W; Wan Y; Mu X; Zhang M
    PLoS One; 2023; 18(9):e0291455. PubMed ID: 37756307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
    Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
    Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients.
    Okano S; Abu-Elmagd K; Kish DD; Keslar K; Baldwin WM; Fairchild RL; Fujiki M; Khanna A; Osman M; Costa G; Fung J; Miller C; Kayashima H; Hashimoto K
    Am J Transplant; 2018 Oct; 18(10):2544-2558. PubMed ID: 29509288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
    Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
    Front Immunol; 2020; 11():1299. PubMed ID: 32719675
    [No Abstract]   [Full Text] [Related]  

  • 15. Endoplasmic reticulum stress induced LOX-1
    Nan J; Xing YF; Hu B; Tang JX; Dong HM; He YM; Ruan DY; Ye QJ; Cai JR; Ma XK; Chen J; Cai XR; Lin ZX; Wu XY; Li X
    Immunology; 2018 May; 154(1):144-155. PubMed ID: 29211299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of myeloid-derived suppressor cells in dengue fever patients.
    Guo PL; Li LH; Li WL; Zhao JC; Hu FY; Zhang FC; Cai WP; Tang XP
    BMC Infect Dis; 2019 Nov; 19(1):926. PubMed ID: 31675923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating CD15
    Tian X; Wang T; Zheng Q; Tao Y; Dai L; Shen H
    Int J Clin Pract; 2021 Aug; 75(8):e14317. PubMed ID: 33960078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.
    Del Bianco P; Pinton L; Magri S; Canè S; Masetto E; Basso D; Padovan M; Volpin F; d'Avella D; Lombardi G; Zagonel V; Bronte V; Della Puppa A; Mandruzzato S
    Front Immunol; 2021; 12():809826. PubMed ID: 35069595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
    Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
    J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.